News from leap therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 05, 2023, 07:00 ET Leap Therapeutics to Participate at Upcoming Investor Conferences

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...

Aug 14, 2023, 07:00 ET Leap Therapeutics Reports Second Quarter 2023 Financial Results

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Jul 12, 2023, 07:00 ET Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, ...

Jun 20, 2023, 12:30 ET Leap Therapeutics Announces Reverse Stock Split

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...

May 25, 2023, 17:10 ET Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the...

May 15, 2023, 07:00 ET Leap Therapeutics Reports First Quarter 2023 Financial Results

Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Apr 26, 2023, 16:05 ET Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that ...

Apr 12, 2023, 07:00 ET Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...

Mar 24, 2023, 07:00 ET Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Mar 16, 2023, 16:05 ET Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...

Jan 17, 2023, 08:00 ET Leap Therapeutics Acquires Flame Biosciences

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and Flame...

Jan 11, 2023, 07:00 ET Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that ...

Nov 21, 2022, 07:00 ET Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...

Nov 14, 2022, 07:00 ET Leap Therapeutics Reports Third Quarter 2022 Financial Results

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Nov 07, 2022, 08:05 ET Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the...

Oct 17, 2022, 07:00 ET Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that ...

Oct 12, 2022, 07:00 ET Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...

Oct 05, 2022, 08:05 ET Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the...

Sep 07, 2022, 07:00 ET Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that ...

Sep 06, 2022, 07:00 ET Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the...

Sep 04, 2022, 18:05 ET Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress

Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding...

Aug 12, 2022, 07:00 ET Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics today announced that...

Aug 12, 2022, 07:00 ET Leap Therapeutics Reports Second Quarter 2022 Financial Results

Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Jul 12, 2022, 07:00 ET Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and BeiGene, Ltd....

Jun 27, 2022, 07:00 ET Leap Therapeutics to Host Virtual R&D Day on July 12, 2022

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that ...